These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials. Tai C, Gan T, Zou L, Sun Y, Zhang Y, Chen W, Li J, Zhang J, Xu Y, Lu H, Xu D. BMC Cardiovasc Disord; 2017 Oct 05; 17(1):257. PubMed ID: 28982370 [Abstract] [Full Text] [Related]
8. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials. Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, Jia J, Yan T, Liu Y, Lin S. Drugs; 2020 Jun 05; 80(8):797-811. PubMed ID: 32333236 [Abstract] [Full Text] [Related]
9. Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies. Hao G, Wang Z, Guo R, Chen Z, Wang X, Zhang L, Li W. BMC Cardiovasc Disord; 2014 Oct 25; 14():148. PubMed ID: 25344747 [Abstract] [Full Text] [Related]
11. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Xue H, Lu Z, Tang WL, Pang LW, Wang GM, Wong GW, Wright JM. Cochrane Database Syst Rev; 2015 Jan 11; 1():CD008170. PubMed ID: 25577154 [Abstract] [Full Text] [Related]
13. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: A PRISMA-compliant systematic review and meta-analysis. Lv X, Zhang Y, Niu Y, Song Q, Zhao Q. Medicine (Baltimore); 2018 Apr 11; 97(15):e0256. PubMed ID: 29642146 [Abstract] [Full Text] [Related]
14. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients. Zhang L, Zeng X, Fu P, Wu HM. Cochrane Database Syst Rev; 2014 Jun 23; 2014(6):CD009120. PubMed ID: 24953826 [Abstract] [Full Text] [Related]
15. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis. Wang K, Hu J, Luo T, Wang Y, Yang S, Qing H, Cheng Q, Li Q. Kidney Blood Press Res; 2018 Jun 23; 43(3):768-779. PubMed ID: 29794446 [Abstract] [Full Text] [Related]
16. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection? Ong HT. J Am Board Fam Med; 2009 Jun 23; 22(6):686-97. PubMed ID: 19897698 [Abstract] [Full Text] [Related]
17. Renin-angiotensin-aldosterone system blockers and cardiovascular outcomes: a meta-analysis of randomized clinical trials. Kızılırmak P, Üresin Y, Özdemir O, Kılıçkıran Avcı B, Tokgözoğlu L, Öngen Z. Turk Kardiyol Dern Ars; 2017 Jan 23; 45(1):49-66. PubMed ID: 28106020 [Abstract] [Full Text] [Related]
18. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials. Shahin Y, Khan JA, Chetter I. Atherosclerosis; 2012 Mar 23; 221(1):18-33. PubMed ID: 22209214 [Abstract] [Full Text] [Related]